RESEARCH LETTER

mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?

Veerle P. W. M. Wijtvliet[1,2], Kevin K. Ariën[3,4], Steven Abrams[5,6], Marie M. Couttenye[1,2], Fabienne Mestrez[7], Joachim Mariën[3,8], Benedicte Y. De Winter[1], Pierre Van Damme[9], Lissa Pipeleers[10], Karl Martin Wissing[10], Daniel Abramowicz[1,2], Kristien J. Ledeganck[1]

[1] Laboratory of Experimental Medicine and Pediatrics and member of the Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium

[2] Department of Nephrology and Hypertension, Antwerp University Hospital, Edegem, Belgium

[3] Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

[4] Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium

[5] Department of Epidemiology and Social Medicine, Global Health Institute, University of Antwerp, Antwerp, Belgium

[6] I-BioStat, Data Science Institute, Hasselt University, Diepenbeek, Belgium

[7] Department of Nephrology-Dialysis, University Hospital (CHU) Ambroise Paré, Mons, Belgium

[8] Evolutionary Ecology Group, Department of Biology, University of Antwerp, Antwerp, Belgium.

[9] Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium

[10] Department of Nephrology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium

Corresponding author: Veerle Wijtvliet, MD. Antwerp University Hospital, Department of Nephrology and Hypertension. Drie Eikenstraat 655, 2650 Edegem, Belgium.

Electronic address: veerle.wijtvliet@uantwerpen.be

Phone number: +32 3 265 2591.

Abstract

In this study of the humoral immune response after the first dose of SARS-CoV-2 mRNA vaccine, low seroconversion rates were noted in both kidney transplant recipients and dialysis patients. However, vaccination with the mRNA-1273 vaccine (Moderna) resulted in both higher seroconversion rates and mean antibody titers compared to BNT162b2 (Pfizer).

Main text

With the roll-out of COVID-19 vaccines, it has become clear that vaccinating the majority of the population worldwide will be the most important element to control and manage the ongoing COVID-19 pandemic. Several reports have shown diminished immunogenicity of SARS-CoV-2 vaccines in both kidney transplant recipients (KTR) and dialysis patients (DP), as evidenced in a recent meta-analysis [1]. Furthermore, two recent articles have included comparisons between the immunogenicity of the mRNA-1273 (Moderna) versus the BNT162b2 (Pfizer) vaccine in these populations [2, 3]. Boyarsky et al. studied a cohort of solid organ transplant recipients, including KTR, and reported lower seroconversion rates after receiving the Pfizer vaccine [3]. Stumpf et al. also described lower seroconversion rates in KTR and DP receiving the Pfizer vaccine [2]. However, none of these articles reported the titers of anti-SARS-CoV-2 antibodies. Therefore, we here compared the immunogenicity of the two available mRNA vaccines BNT162b2 (Pfizer-BioNTech) versus mRNA-1273 (Moderna) in both KTR and DP regarding both seroconversion rates and, among responding patients, antibody titers.

A random sample of 143 KTR and 178 DP receiving a first dose of a SARS-CoV-2 mRNA vaccine between February and April 2021 was included. Blood was sampled at day 1 (before vaccination) and 21 days thereafter. Samples were stored at "Biobank Antwerp", Antwerp, Belgium; ID: BE 71030031000 [4]. Immunoglobulin G (IgG) antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein were measured using an in-house Luminex assay [5]. In order to investigate only patients without prior SARS-CoV-2 infection, we excluded 1) patients with a PCR-proven history of SARS-CoV-2 infection (n = 37) and 2) patients who tested positive for anti-RBD IgG antibodies (> 1) at the day of vaccination without a PCR-proven history of SARS-CoV-2 infection (n = 16), as a surrogate of previous SARS-CoV-2 infection. Response to first vaccination was defined as anti-RBD IgG positivity (signal-to-noise ratio > 1) at day 21. The study was performed in accordance with the Declaration of Helsinki and approved by the ethical committee of the Antwerp University Hospital and University of Antwerp (no. EC 21/05/076).

Multiple logistic regression modelling was used to identify variables associated with a positive antibody response. A multiple linear regression approach was used to study factors influencing log-transformed anti-RBD IgG levels in responding patients. Potentially important factors were first identified using a bivariate analysis (with effect sizes expressed as crude Odds Ratios (ORs) or additive effects, respectively). Next to that, a stepwise model building exercise based on Akaike's Information Criterion (AIC) was used to select all important explanatory variables in the final models. Depending on the selected covariates, all pairwise interaction effects were checked for significance. All statistical tests were two-sided. A p-value < 0.05 was considered statistically significant.

In total, 127 KTR, 103 patients on haemodialysis and 38 patients on peritoneal dialysis were included (**Table 1**). The median age of all included patients was 63 years (interquartile range (IQR), 51-72 years) and 61% were men. Sixty-two percent received the BNT162b2 vaccine (Pfizer-BioNTech), 38% received the mRNA-1273 vaccine (Moderna). At a median of 21 days (IQR, 20-23 days) anti-RBD IgG antibodies were detected in 79 out of 268 participants (29%, Clopper-Pearson 95% CI, 24-35%). Both haemodialysis patients (adjusted OR, 7.413 (95% CI, 3.342-16.443); $p < 0.001$) and peritoneal dialysis patients (adjusted OR, 11.500 (95% CI, 4.484-29.497; $p < 0.001$) were more likely to develop antibody responses compared to KTR (**Table 2A)**. Furthermore, the odds of having an antibody response decreased with a factor 0.972 (95% CI, 0.950-0.995) with a one-year increase in age. Patients receiving the mRNA-1273 vaccine (Moderna) showed significantly different seroconversion rates 21 days after dose 1 compared to patients receiving the BNT162b2 vaccine (Pfizer-BioNTech) (50% versus 16.9%; adjusted OR, 5.074 (95% CI, 2.726-9.446); $p < 0.001$). After selecting patients with an antibody response ($n = 79$), the mRNA-1273 vaccine resulted in a higher mean (log-transformed) anti-RBD IgG antibody level compared to the BNT162b2 (Pfizer) vaccine ($p = 0.029$). The mean log-transformed anti-RBD IgG antibody level was significantly different between both vaccines (**Table 2B**; **Figure 1**). All pairwise interaction terms included in both models were found to be non-significant at a 5% significance level.

In this study of the humoral immune response after the first dose of SARS-CoV-2 mRNA vaccine, low seroconversion rates were noted in both KTR and DP. However, vaccination with the mRNA-1273 vaccine (Moderna) resulted in both higher seroconversion rates and mean antibody titers. From a bivariate perspective, a pronounced difference in mean antibody titers for both vaccines was present in DP, but no significant difference was found in KTR.

Nevertheless, the lack of a statistically significant difference in this group may be due to inadequate power, as the number of seroconverting KTR was small (i.e. n = 7 vs. n = 9 for Pfizer and Moderna, respectively, Table 2A) and the spread in antibody titer values was considerable (**Figure 1**). More research is required to investigate these differences further in detail based on larger samples of KTR.

While writing this discussion, two very recently articles were published, which support our above-mentioned findings [6, 7]. First, seroconversion rates in adults with hematologic malignant disease, whom in majority received B-cell-depleting monoclonal Abs, were higher in patients vaccinated with mRNA-1273 (Moderna) compared to BNT162b2 (Pfizer) (50% vs. 33%, p=0.013) [6]. Second, a study of individuals in the multi-state Mayo Clinic Health System revealed that the mRNA-1273 vaccine was associated with a lower incidence of SARS-CoV-2 infection (p=0.0034) as well as with a significant two-fold risk reduction against breakthrough infection compared to BNT162b2 [7]. Whether observed differences between these two mRNA-vaccines relate to a different mRNA sequence, a difference in dosage (100 μg mRNA in Moderna vs. 30 μg mRNA in Pfizer) or a difference in vaccine composition, remains to be investigated. Furthermore, future studies are needed to assess whether our observed differences remain identical 21 days after a second dose of mRNA vaccine; and whether they are associated with a better clinical protection. Meanwhile, mRNA-1273 (Moderna) might be the preferred vaccine in kidney transplant and dialysis patients.

Acknowledgements:

The authors would like to thank study nurses E. Meersman, S. Verhofstede, N. Marmitte and T. Bogaerts for their excellent and efficient help. We also thank E. Snelders, S. Van Hees and J. Michiels for their logistical support, the lab technicians of the Lab of Experimental Medicine and Pediatrics for the sample processing and P. Moons from Biobank Antwerp for his technical support. Special thanks to all the kidney transplant recipients and dialysis patients who made this study possible.

Conflict of interest statement: none declared. Furthermore, this paper has not been published previously in whole or part.

Funding

The authors received no specific funding for this work.

Data availability statement

Requests for original and additional data should be directed to the corresponding author.

References

1. Carr EJ, Kronbichler A, Graham-Brown M*, et al.* Systematic Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients with Chronic Kidney Disease. Kidney Int Rep 2021
2. Stumpf J, Siepmann T, Lindner T*, et al.* Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur 2021:100178
3. Boyarsky BJ, Werbel WA, Avery RK*, et al.* Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. Jama 2021;325(21):2204-2206
4. BE 71030031000; Biobank Antwerp [BB190007], BBMR-ERIC, Belgian [BIORESOURCE].
5. Mariën J, Ceulemans A, Michiels J*, et al.* Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay. J Virol Methods 2021;288:114025
6. Ollila TA, Lu S, Masel R*, et al.* Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease. JAMA Oncol 2021
7. Puranik A, Lenehan PJ, Silvert E*, et al.* Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv 2021

Table 1: Baseline characteristics

	mRNA-1273 (Moderna)	BNT162b2 vaccine (Pfizer-BioNTech)	*p*-Value
Kidney transplant recipients			
Number of subjects	41	86	
Male (n (%))	24 (58.5)	48 (55.8)	0.772*
Median age, years (IQR)	57 (49.5-61.0)	56 (46.0-67.3)	0.385**
Diabetes mellitus (n (%))	2 (4.9)	10 (11.6)	0.224*
Immunosuppressive therapy (n (%))			
CNI	6 (14.6)	21 (24.4)	0.208*
CNI + MMF/AZA/mTOR inhibitor	31 (75.6)	53 (61.6)	0.120*
Positive antibody response (n (%))	9 (22.0)	7 (8.1)	**0.028***
Anti-RBD IgG antibody levels† (median (IQR))	3.13 (1.92-7.83)	4.09 (2.44-6.37)	0.681**
Anti-RBD IgG antibody levels† (geometric mean (GSD))	3.61 (2.10)	4.00 (1.73)	0.766***
Dialysis patients			
Number of subjects	61	80	
Male (n (%))	39 (63.9)	53 (66.3)	0.775*
Median age, years (IQR)	69 (60.0-77.5)	70 (62.0-75.0)	0.845**
Haemodialysis (n (%))	40 (65.6)	63 (78.8)	0.081*
Diabetes mellitus (n (%))	29 (47.5)	28 (35.0)	0.133*
Positive antibody response (n (%))	42 (68.9)	21 (26.3)	**< 0.001***
Anti-RBD IgG antibody levels† (median (IQR))	7.47 (3.26-10.99)	3.03 (1.82-5.05)	**0.008****
Anti-RBD IgG antibody levels† (geometric mean (GSD))	5.39 (2.27)	3.17 (1.91)	**0.012*****
Total			
Number of subjects	102	166	
Male (n (%))	63 (61.8)	101 (60.8)	0.881*
Median age, years (IQR)	61.5 (50.8-72.0)	64.5 (52.5-71.2)	0.818**
Diabetes mellitus (n (%))	31 (30.4)	38 (22.9)	0.173*
Positive antibody response (n (%))	51 (50.0)	28 (16.9)	**< 0.001***
Anti-RBD IgG antibody levels† (median (IQR))	5.80 (2.40-10.54)	3.28 (1.99-5.74)	**0.016****
Anti-RBD IgG antibody levels† (geometric mean (GSD))	5.02 (2.26)	3.36 (1.86)	**0.026*****

† In responding patients

* Based on Pearson's Chi-square test

** Based on Mann-Whitney U test
*** Based on an unpaired Student's t-test comparing two mean log-GMTs

Abbreviations: AZA = azathioprine ; CS = corticosteroids ; CNI = calcineurin inhibitors ; GSD = geometric standard deviation; IgG = immunoglobulins G ; IQR = interquartile range ; MMF = mycophenolate mofetil; mTOR = mechanistic target of rapamycin; n = number ; RBD = receptor binding domain ; SD = standard deviation

Table 2.

A: Multiple logistic regression model for factors associated with antibody response to the first dose of SARS-CoV-2 Messenger RNA vaccine

Covariates	No Antibody Response (n = 189)	Antibody response (n = 79)	Crude OR (95% CI)	*p*-Value	Adjusted OR (95% CI)	*p*-Value
Type of patient Kidney transplant Haemodialysis Peritoneal dialysis	 111 (58.7%) 62 (32.8%) 16 (8.5%)	 16 (20.3%) 41 (51.9%) 22 (27.8%)	 Ref 4.588 (2.381-8.841) 9.539 (4.158-21.883)	 Ref <0.001 <0.001 Overall* <0.001	 Ref 7.413 (3.342-16.443) 11.500 (4.484-29.497)	 Ref **<0.001** **<0.001** Overall* **<0.001**
Gender Male Female	 110 (58,2%) 79 (41.8%)	 54 (68.4%) 25 (31.6%)	 Ref 0.644 (0.370-1.123)	 Ref 0.121	NA	NA
Age: median (IQR) (years)	63 (52-71)	62 (50-73)	1.000 (0.983-1.018)	0.943	0.972 (0.950-0.995)	**0.0167**
Diabetes mellitus No Yes	 144 (76.2%) 45 (23.8%)	 55 (69.6%) 24 (30.4%)	 Ref 1.396 (0.778-2.506)	 Ref 0.263	NA	NA
Vaccine Type Pfizer Moderna	 138 (73.0) 51 (27.0)	 28 (35.4%) 51 (64.6%)	 Ref 4.929 (2.810-8.644)	 Ref <0.001	 Ref 5.074 (2.726-9.446)	 Ref **<0.001**

* Based on an overall likelihood ratio test

Abbreviations: CI = confidence interval: IQR = interquartile range; n = number; NA = not applicable; OR = odds ratio; Ref = reference

B: Multiple linear regression model for factors associated with antibody levels after first dose of SARS-CoV-2 Messenger RNA vaccine

	Univariable analysis		Multivariable analysis	
Covariates	**Standardized Beta**	***p*-Value**	**Standardized Beta**	***p*-Value**
Type of patient Kidney transplant Haemodialysis Peritoneal dialysis	Ref 0.143 0.398	Ref 0.630 0.231 Overall* 0.451	NA	NA
Gender Male Female	Ref 0.116	Ref 0.634	NA	NA
Age: median (IQR) (years)	-0.282	0.011	-0.269	**0.014**
Diabetes mellitus No Yes	Ref -0.197	Ref 0.424	NA	NA
Vaccine Type Pfizer Moderna	Ref 0.522	Ref 0.026	Ref 0.493	Ref **0.029**

* Based on an overall partial F-test

Abbreviations: CI = confidence interval: IQR = interquartile range; n = number; NA = not applicable; OR = odds ratio; Ref = reference

Legends to figures

Figure 1: Anti-RBD IgG levels in patients receiving BNT162b2 (Pfizer) versus mRNA-1273 (Moderna) vaccine.

Abbreviations: IgG = immunoglobulins G; RBD = receptor binding domain

Figure 1:


A) Overall
p < 0.05
anti-RBD IgG antibody levels
15
10
5
0
BNT162b2
mRNA-1273
B) Kidney transplant recipients
p > 0.05
anti-RBD IgG antibody levels
15
10
5
0
BNT162b2
mRNA-1273
C) Dialysis patients
p < 0.01
anti-RBD IgG antibody levels
15
10
5
0
BNT162b2
mRNA-1273